Immunomodulatory drugs (IMiDs) are thalidomide analogues that retain the direct anticancer cytotoxic and immunological activity of their parent compound, but with a different toxicity profile. In vitro studies show that IMiDs have a more potent antitumour effect than thalidomide on multiple myeloma (MM...
Immunomodulatory drugs (IMiDs) include thalidomide, lenalidomide, and pomalidomide, which have shown significant efficacy in the treatment of multiple myeloma (MM), myelodysplastic syndrome (MDS) with deletion of chromosome 5q (del(5q)) and other hematological malignancies. IMiDs hijack the CRL4CRBNub...
Despite progress due to development of proteasome inhibitors (bortezomib, carfilzomib) and immunomodulatory drugs (IMiDs; thalidomide, lenalidomide, pomalidomide), novel combination treatment strategies are needed to further improve multiple myeloma (MM) patient outcome. Recent studies have shown cereblon to ...
Immunomodulatory drugs (IMiD) are a novel class of orally available antineoplastic agents that have made an important impact on the treatment of patients with hematological malignancies, particularly multiple myeloma (MM). The parent compound, thalidomide, was the first to demonstrate antineoplastic activi...
摘要: The effect of immunomodulatory drugs (IMiDs) on serious infection remains uncertain. We therefore conducted a systematic review and meta-analysis to assess the possible impact of IMiDs on serious...关键词: Immunomodulatory drug Infection Multiple myeloma Systematic review Meta-analysis ...
Immunomodulatory drugs (IMiDs) in multiple myeloma: mechanism of action and clinical implications Immunomodulatory drugs (IMiDs) are a class of drugs, derived from the teratogenic compound thalidomide, that have made a major impact on treatment of many diseases, from multiple myeloma to assorted inflam...
In the last decade the introduction of novel agents has strongly improved multiple myeloma prognosis by doubling median overall survival. Unfortunately disease relapse is very common and patients may become refractory to previous drugs. Therefore, new therapeutic strategies are urgently needed. Areas ...
Internal ribosome entry site of bFGF is the target of thalidomide for IMiDs development in multiple myeloma Although new analogues of immunomodulatory drugs (IMiDs) are being developed for MM, the molecular mechanism of these drugs remains unclear. In the current... IC Lien,LY Horng,PL Hsu,.....
Patients with multiple myeloma are at high risk of developing venous thromboembolism (VTE) owing to patient disease and treatment including immunomodulatory drugs (IMiDs). In early 2020, the National Comprehensive Cancer Network (NCCN) adopted the IMPEDE risk assessment for VTE prevention in multiple ...
Immunomodulatory drugs (IMiDs) including lenalidomide and pomalidomide bind cereblon (CRBN) and activate the CRL4ubiquitin ligase to trigger proteasomal degradation of the essential transcription factors IKZF1 and IKZF3 and multiple myeloma (MM) cytotoxicity. We have shown that CRBN is also targeted ...